与人类绝经期促性腺激素相比，使用高纯度人卵泡刺激素进行卵泡刺激后行卵胞浆内单精子注射。

Intracytoplasmic sperm injection after follicle stimulation with highly purified human follicle-stimulating hormone compared with human menopausal gonadotropin.

作者信息

Weissman A, Meriano J, Ward S, Gotlieb L, Casper R F

机构信息

Department of Obstetrics and Gynecology, Toronto Hospital, Ontario, Canada.

出版信息

J Assist Reprod Genet. 1999 Feb;16(2):63-8. doi: 10.1023/a:1022560621444.

DOI:10.1023/a:1022560621444

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3455738/

Abstract

PURPOSE

Our purpose was to compare oocyte nuclear maturation and embryo quality after pituitary down-regulation and ovarian stimulation with highly purified follicle-stimulating hormone (FSH) or human menopausal gonadotropin (HMG).

METHODS

Fifty-five patients 37 years of age or younger who were undergoing in vitro fertilization (IVF)-intracytoplasmic sperm injection (ICSI) were evaluated retrospectively. In all cases, male factor was the only indication for treatment, with no female-related factors identified. Following pituitary down-regulation, patients were stimulated with hMG (n = 20) or highly purified FSH (n = 35). Main outcome measures included ovarian response to stimulation, oocyte maturity, and ICSI fertilization results. Secondary outcome measures included pregnancy rates and outcome.

RESULTS

The ovarian response to stimulation was similar for the two groups, as were the percentage of metaphase II oocytes, fertilization and cleavage rates, and number and quality of transferred and cryopreserved embryos. Cycle outcome was comparable.

CONCLUSIONS

In normogonadotropic subjects, monocomponent therapy with highly purified FSH is as effective as hMG in stimulating ovarian follicular development, synchronization of oocyte maturation, and IVF-ICSI outcome. Our findings support the conclusion that the luteinizing hormone component in the stimulation protocol is unnecessary.

摘要

目的

我们的目的是比较垂体降调节及卵巢刺激后，使用高纯度促卵泡激素（FSH）或人绝经期促性腺激素（HMG）时的卵母细胞核成熟情况及胚胎质量。

方法

回顾性评估了55例37岁及以下接受体外受精（IVF）-卵胞浆内单精子注射（ICSI）的患者。所有病例中，男性因素是唯一的治疗指征，未发现与女性相关的因素。垂体降调节后，患者分别接受HMG（n = 20）或高纯度FSH（n = 35）刺激。主要观察指标包括卵巢对刺激的反应、卵母细胞成熟度及ICSI受精结果。次要观察指标包括妊娠率及结局。

结果

两组的卵巢对刺激的反应相似，中期II卵母细胞百分比、受精及分裂率，以及移植和冷冻保存胚胎的数量及质量也相似。周期结局相当。

结论

在正常促性腺激素水平的受试者中，高纯度FSH单组分疗法在刺激卵巢卵泡发育、卵母细胞成熟同步化及IVF-ICSI结局方面与HMG一样有效。我们的研究结果支持以下结论：刺激方案中的黄体生成素组分是不必要的。

相似文献

1

Intracytoplasmic sperm injection after follicle stimulation with highly purified human follicle-stimulating hormone compared with human menopausal gonadotropin.

J Assist Reprod Genet. 1999 Feb;16(2):63-8. doi: 10.1023/a:1022560621444.

2

Nuclear maturity and oocyte morphology after stimulation with highly purified follicle stimulating hormone compared to human menopausal gonadotrophin.

Hum Reprod. 1996 Nov;11(11):2387-91. doi: 10.1093/oxfordjournals.humrep.a019120.

3

[Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].

Zhonghua Fu Chan Ke Za Zhi. 2013 Nov;48(11):838-42.

4

Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI.

Acta Obstet Gynecol Scand. 2010 Aug;89(8):1053-60. doi: 10.3109/00016349.2010.499450.

5

Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study.

Fertil Steril. 2001 Sep;76(3):543-9. doi: 10.1016/s0015-0282(01)01973-2.

6

Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.

Fertil Steril. 2008 Jun;89(6):1685-93. doi: 10.1016/j.fertnstert.2007.05.039. Epub 2007 Aug 6.

7

Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.

Gynecol Endocrinol. 1998 Feb;12(1):9-15. doi: 10.3109/09513599809024964.

8

A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins.

Fertil Steril. 2001 Jun;75(6):1131-5. doi: 10.1016/s0015-0282(01)01788-5.

9

A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.

Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:70-3. doi: 10.1016/j.ejogrb.2013.10.027. Epub 2013 Nov 5.

10

The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.

Hum Reprod. 1996 Jun;11(6):1209-13. doi: 10.1093/oxfordjournals.humrep.a019357.

本文引用的文献

1

Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.

Hum Reprod. 1997 Oct;12(10):2133-9. doi: 10.1093/humrep/12.10.2133.

2

Improved oocyte quality is obtained with follicle stimulating hormone alone than with follicle stimulating hormone/human menopausal gonadotrophin combination.

Hum Reprod. 1997 Sep;12(9):1886-9. doi: 10.1093/humrep/12.9.1886.

3

Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome.

Fertil Steril. 1997 May;67(5):889-99. doi: 10.1016/s0015-0282(97)81402-1.

4

Nuclear maturity and oocyte morphology after stimulation with highly purified follicle stimulating hormone compared to human menopausal gonadotrophin.

Hum Reprod. 1996 Nov;11(11):2387-91. doi: 10.1093/oxfordjournals.humrep.a019120.

5

A randomized comparative study of highly purified follicle stimulating hormone and human menopausal gonadotrophin for ovarian hyperstimulation in an oocyte donation programme.

Hum Reprod. 1996 Sep;11(9):1864-70. doi: 10.1093/oxfordjournals.humrep.a019508.

6

Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity.

Hum Reprod. 1996 Sep;11(9):1854-8. doi: 10.1093/oxfordjournals.humrep.a019506.

7

Controlled ovarian stimulation using highly purified FSH results in a lower serum oestradiol profile in the follicular phase as compared with HMG.

Hum Reprod. 1996 Mar;11(3):474-7. doi: 10.1093/humrep/11.3.474.

8

The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.

Hum Reprod. 1996 Jun;11(6):1209-13. doi: 10.1093/oxfordjournals.humrep.a019357.

9

A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.

Hum Reprod. 1995 Oct;10(10):2534-40. doi: 10.1093/oxfordjournals.humrep.a135740.

10

Simplifying in-vitro fertilization therapy.

Curr Opin Obstet Gynecol. 1994 Apr;6(2):111-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。